Study: Saffran modulates fear and depression powerfully

Veröffentlicht:

Von:

Referenz Ghajar A, Neishabouri SM, Velayati N, et al. Crocus sativus L. versus Citalopram bei der Behandlung von schweren depressiven Störungen mit Angstzuständen: eine doppelblinde, kontrollierte klinische Studie. Pharmakopsychiatrie. 4. Oktober 2016. [Epub ahead of print]. Design Randomisierte, doppelblinde, kontrollierte klinische Studie Teilnehmer Ermittler in Teheran, Iran, rekrutierten 66 Männer und Frauen im Alter von 18 bis 65 Jahren mit der Diagnose einer leichten bis mittelschweren schweren Depression mit Angstzuständen. Sie wurden randomisiert, um entweder einen selektiven Serotonin-Wiederaufnahmehemmer (SSRI; Citalopram, 20 mg) oder Safran (Crocus sativus L. standardisiert auf 1,65-1,75 mg Crocin pro Kapsel) Extrakt (15 mg) 2 mal täglich …
Reference Ghajar A, Neishabouri SM, Velayati n, et al. Crocus Sativus L. Versus Citalopram in the treatment of severe depressive disorders with anxiety: a double -blind, controlled clinical study. Pharmacopsychiatry. October 4, 2016. [Epub Ahead of Print]. Design randomized, double -blind, controlled clinical study participants Investigators in Tehran, Iran, recruited 66 men and women between the ages of 18 and 65 with the diagnosis of a slight to moderate severe depression with anxiety. They were randomized to either a selective serotonin reuptake inhibitor (SSRI; Citalopram, 20 mg) or saffron (Crocus Sativus L. standardized on 1.65-1.75 mg crocin per capsule) extract (15 mg) twice a day ... (Symbolbild/natur.wiki)

Reference

ghajar a, Neishabouri SM, Velayati n, et al. Crocus Sativus L. Versus Citalopram in the treatment of severe depressive disorders with anxiety: a double -blind, controlled clinical study. pharmacopsychiatry . October 4, 2016. [Epub Ahead of Print].

Design

randomized, double -blind, controlled clinical study

participant

Investigators in Tehran, Iran, recruited 66 men and women between the ages of 18 and 65 with the diagnosis of slight to moderate severe depression with anxiety. They were randomized to either a selective serotonin reuptake inhibitor (SSRI; Citalopram, 20 mg) or saffron ( crocus sativus l . 30 participants in each group ended the study.
The exclusion criteria was to take antidepressants in the previous month; Preservation of electrical stamping therapy (EKT) in the past 2 months; Diagnosis of other mental disorders in the diagnostic and statistical manual of mental disorders (DSM) IV axis I; Alcohol or substance dependency (with the exception of nicotine); And severe depression or suicide thoughts. The participants were not allowed to use other psychotropic drugs during the course of study or undergo behavioral therapy intervention therapy.

study parameters evaluated

The participants were assessed using the Hamilton Rating Scale for Depression (Ham-D) and the Hamilton Rating Scale for Anxiety (Ham-A) at the beginning of the course and then again after 2, 4 and 6 weeks.

target parameter

The primary endpoint was the effectiveness of saffron when improving depression and anxiety symptoms during the study compared to citalopram, which was used as a comparison preparation, since it has the best combination of high effectiveness and low side effects in this population.
The changes of Ham-D and Ham-A from the starting value at any time as well as the response to treatment (defined as ≥50 % reduction of the Ham-D scores) and remission (defined as Ham-D score ≤ 7). Prices between the treatment groups.

important knowledge

anxiety and depression at the beginning of the course were equivalent in the saffron and comparison group. The symptoms of both depression and anxiety improved significantly over the period of 6 weeks, in the same quantities in both groups.
In week 6, 90 % of the Citalopram Group and 73 % of the Safran Group found a reduction in their Ham-D score by ≥ 50 %, a non-significant difference ( p = 0.18). Also in week 6 there were 87 % of the citalopram group and 63 % of the saffron group in remission (Ham-D ≤ 7), which tended to citalopram, but did not achieve significance in favor of Citalopram ( p = 0.07).

saffron was first mentioned in the Papyrus Ebers over 3,500 years ago as a "encouraging heart remedy".

The fear decreased significantly in both groups. After 6 weeks, the Ham-A scores fell from 19.1 to 7.0 in the citalopram group and from 19.7 to 7.6 in the saffron group.
The undesirable events were comparable in both groups, there were no serious events and no events that were common enough to achieve statistical significance, although 16.7 % of the citalopram group suffered from dizziness (and none in the saffron group), which led to a tendency, but did not achieve any significance ( p = 0.052).

practice implications

clinical fear and clinical depression often come together, which DSM-5 calls severe depression with anxious burden. Patients with depression and anxiety have worse results than patients with depression or anxiety alone - worse illness, more serious undesirable events and side effects and less common remission.
an SSRIs plus placebo was previously compared with an SSRIs plus crocin (the ingredient on which the saffron was standardized in this study), and the group that received crocine experienced a significantly stronger improvement in the symptoms of depression and anxiety with advantages for general health. Saffran for severe depressive disorders a large effect size compared to placebo and non-subdness compared to pharmaceutical antidepressants.
This present study, the first that Safran compares with an active comparison preparation in patients with depression and anxiety, shows that saffron, as the sole intervention, can not only significantly improve the symptoms of depression, but also from anxiety, possibly as much as you could improve with a therapeutic dose of citalopram.
The mechanisms of action of saffron can include serotonians, antioxidant, anti -inflammatory, neuroendocrine and neuroprotective effects. 4 It was examined as an antitumor. Snack behavior. 6
saffron was first mentioned as a medicine in the papyrus of Ebers over 3,500 years ago and has been used safely for a very long time-no serious undesirable events were associated with its use, no clinically significant undesirable events were associated with the short-term use of moderate doses, and the estimated LD-50 (deadly dose, 50 %; Quantity that would kill half of the test subjects) is 1.4 kg for a 150 pound man. There are texts that warn of the dangers of saffron, but these are probably mixing the topic of this article, our "saffron" ( crocus sativus l. ), a crocus, blossoming in autumn, with "autumn time" ( Colchicum autumnale ), which is not a real crocus, but also in autumn bloom. 8
How should we dose this safe, effective herb for our anxious, depressive patients in clinical practice? The authors of this study use a daily dose of 30 mg of a saff -chip extract, standardized for a total of around 3.4 mg crocin. Other groups have also found favorable results with extracts from the flower leaves of the flower. 9 If we have no access to a standardized extract from a trustworthy source, we can turn to the spice ourselves, all the dried scars that are available for culinary use. Culinary saffron can vary between 13 mg and 109 mg crocin (including all crocines that were detected at 440 η m) per gram stamp, 10 Most dried Iranian saffron stamps contain more often about 35 mg crocines per gram.
With a concentration of 35 mg crocin per gram of saffron stamps, we would have to prescribe 100 mg twice a day in order to meet the crocin dose used in this study. Large (link away) sell saffron for $ 120 per ounce; This corresponds to 280 doses of saffron, about 86 cents a day or $ 26 a month-about twice as much as Citalopram, but still affordable. 12 Even this small dose can be exaggerated; A study showed that the mere sniffing of non -detectable amounts of saffron was able to demonstrably reduce anxiety.
by weight this is the most expensive spice in the world, but it seems to be strong enough that it is relatively affordable, in addition that it is safe and effective. We should expect a treatment period of 4 to 6 weeks before our patients begin to notice a significant difference.
Note from the editor: This page was updated on December 16, 2016 to correct the monthly and daily costs for saffron.

  1. fava m, rush aj, alpert je, et al. Difference in treatment results in outpatient patients with anxious not anxious depression: a star*D report. am J Psychiatrie . 2008; 165 (3): 342-351.
  2. Talaei A., Hassanpour Moghadam M., Sajadi Tabassi Sa, Mohajeri Sa. Crocin, the most important active saffron component, as an additional treatment for severe depressive disorders: a randomized, double -blind, placebo -controlled clinical pilot study. j affect disord . 2015; 174: 51-56.
  3. Hausenblas Ha, Saha d, Dubyak PJ, Anton Sd. Saffran (Crocus Sativus L.) and Major Depression: A meta-analysis of randomized clinical studies. j Integr. Med . 2013; 11 (6): 377-383.
  4. Lopresti al, drummond pd. Saffran (Crocus Sativus) for depression: A systematic review of clinical studies and examination of the underlying antidepressant mechanisms of action. hum Psychopharmacol . 2014; 29 (6): 517-527.
  5. Bolhassani A., Khavari A., Bathaie sz. Saffran and natural carotenoids: biochemical activities and antitumer effects. Biochim Biophys Acta . 2014; 1845 (1): 20-30.
  6. Hausenblas Ha, Heekin K, Mutchie Hl, Anton S. A systematic review of randomized controlled studies to examine the effectiveness of saffron (Crocussativus L.) on psychological and behavioral results. j Integr. Med . 2015; 13 (4): 231-240.
  7. Srivastava R., Ahmed H., Dixit RK, Dharamveer, Saraf Sat. Crocus Sativus L.: A comprehensive overview. pharmacogn rev . 2010; 4 (8): 200-208.
  8. Dharmananda S. Safran: an antidepressant. Website of the Institute for Traditional Medicine. (Link away). Published in May 2005. Access on November 14, 2016.
  9. Akhondzadeh Basti a, Moshiri e, Noorbala aa, Jamshidi Ah, Abbasi SH, Akhondzadeh S. Comparison of petals by Crocus Sativus L. and Fluoxetin In the treatment of depressive outpatient patients: a randomized double-blind study. Prog neuropsychopharmacol biiol psychiatry . 2007; 31 (2): 439-442.
  10. Caballero-Ortega H., Pereda-Miranda R., Riverón-Negrete L., Abdullaev fi. Chemical composition of saffron (Crocus Sativus L.) from four countries. acta horticulturae . 2004; 650 (650): 321-326.
  11. Hadizadeh f, mahdavi m, emam sa. Evaluation of the ISO method in the saffron qualification. acta horticulturae . 2007; 739: 405-410.
  12. drug cost estimates-generic. Blue Cross Blue Shield of Illinois website. (Link away). Accessed on November 14, 2016.
  13. Fukui H, Toyoshima K, Komaki R. Psychological and neuroendocrinological effects of the smell of Safran (Crocus Sativus). phytomedicine . 2011; 18 (8-9): 726-730.